68GA PSMA 11; Illucix which is used as the comparator for SoC in this trial just posted quarter revenue of 50m US, but only launched April 2022.
Telix Pharmaceuticals, who own Illucix, currently sitting at 2B.
Pylarify, which they have used as an example in their most recent presentation may have a revenue of 500m US for Lantheus in 2022.
@Davisite Do you know why Clarity used 68GA PSMA 11 rather than Piflufolastat F-18 for their comparator?
Ann: PROPELLER Trial Results, page-3
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$5.22 |
Change
-0.140(2.61%) |
Mkt cap ! $1.625B | |||
| Open | High | Low | Value | Volume |
| $5.36 | $5.50 | $5.18 | $5.452M | 1.028M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6927 | $5.22 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.26 | 4319 | 1 |
View Market Depth
| Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$5.22 |
Change
-0.140 ( 1.59 %) |
||||
| Open | High | Low | Volume | ||
| $5.34 | $5.49 | $5.19 | 94951 | ||
| Last updated 15.59pm 14/06/2024 ? | |||||
| CU6 (ASX) Chart |